Table 2. Summary of findings
	Absolute chance/risk (95% CI)a		RR (95% CI)	N participants/studies	Interpretation	Quality of evidence
	Vaginal progesterone capsules	Oral dydrogesterone
Live birth/Ongoing pregnancy	24%	25% (22-30%)	1.08 (0.92-1.26)	3,386/8	Dydrogesterone is better or no clinically relevant difference	High
Clinical pregnancy	28%	31% (27-36%)	1.10 (0.95-1.27)	4,061/9	Dydrogesterone is better or no clinically relevant difference	High
Miscarriage per clinical pregnancy	17%	16% (11-21%)	0.92 (0.68-1.26)	988/8	No clinically relevant difference	Moderate1
Dissatisfaction	One study showing a large reduction (RR=0.10, 95%CI=0.02-0.39) and the other study showing no significant difference (RR=1.19, 95%CI=0.46-3.04)
All outcomes, except miscarriage, were analyzed per randomized women. CI = confidence interval; RR = relative risk; a = The absolute risk in the Vaginal Progesterone group was determined as the mean risk in these groups; the absolute risk in the Oral Dydrogesterone group and its 95% CI was determined using the RR and its 95% CI; 1. Downgraded one level because of imprecision.